Search
Ancestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawn[T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087] … It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigational[A242432] It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis. … Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the
Amphotericin B
go.drugbank.com/drugs/DB00681ApprovedInvestigationalThe antibiotic is without effect on bacteria, rickettsiae, and viruses. … Amphotericin B shows a high order of in vitro activity against many species of fungi.
Categories: Compounds used in a research, industrial, or household settingPhendimetrazine
go.drugbank.com/drugs/DB01579ApprovedIllicitPhendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.
Brotizolam
go.drugbank.com/drugs/DB09017ApprovedWithdrawnBrotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. … Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours).
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata. … [A264108] The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway has been implicated in the pathophysiology of alopecia areata, as it regulates the expression of inflammatory
Synonyms: D8-ruxolitinib, -(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (.beta.r)-Strawberry
go.drugbank.com/drugs/DB10571ApprovedStrawberry allergenic extract is used in allergenic testing.
Mixtures: Extrait De FraisesCategories: Non-Standardized Food Allergenic ExtractRemimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigationalRemimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. … [A214857] These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed.
Trofinetide
go.drugbank.com/drugs/DB06045Approved[A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … [L64112] The European Commission granted marketing authorization on August 24, 2026 for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged 5 years and older
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026. … [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain.
Synonyms: 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, N-[5-[[4-(1-Cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-2-propenamide